Lineage Cell Therapeutics, Inc.

AMEX:LCTX

Biotechnology

Healthcare
$0.84 -2.80%

-$0.04 today

Market cap
$212.10M
Beta
1.51
P/E (TTM)
-4.6
EPS (TTM)
-$0.26
52W Low $0.85High $2.09

Volume 1.22M

Average 1.19M

LCTX Operating Income

Profit from core operations after operating expenses, before interest and taxes.

Lineage Cell Therapeutics, Inc.AMEX: LCTX

Operating Income · Q1 FY2026 · quarter ended Mar 2026

Operating income remains negative

Q1 FY2026 operating income was -$7.59M, compared with -$6.51M a year earlier. Trailing-twelve-month operating income was -$37.71M.

Context

  • Operating income amounted to 149.6% of revenue in FY2025, down 76.5 pp from a year earlier.
  • Operating income grew in size in 2 of the last 3 fiscal years.

What to watch

Whether operating income reaches the consensus estimate from 4 analysts of -$9.86M (+54.7%) for the fiscal year ending Dec 2026, a step up from the -1.4% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$7.59M-16.0% QoQ
Last fiscal yearDec 2025
-$21.78M-1.4% YoY
LTMMar 2026
-$37.71M-76.8% YoY
Operating Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-16.7%+81.8%+98.5 pp
1 year-1.4%+54.7%+56.1 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Operating Income history

USD · from the income statement

Latest · FY2025
(21.78M) USD
Year-over-year change
-1.4%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Operating Income vs competitors

How LCTX compares with its peers on the latest reported figures

  • LCTX's LTM Mar 2026 operating income of -$37.71M is the highest of the 4 companies compared; the peer median is -$61.31M.
  • Its year-over-year change of -76.8% is the 3rd highest of 4, against a peer median of -59.8%.
  • Operating income amounts to 255.1% of revenue for LCTX, versus a peer median of 136.9%.
LCTX Competitors Peer median
Operating Income for LCTX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
LCTXLineage Cell Therapeutics, Inc.LTM Mar 2026-$37.71M -76.8%—255.1%
MESOMesoblast LimitedLTM Jun 2026-$51.5M +53.2%—42.8%
CELUCelularity Inc.LTM Dec 2025-$61.31M -59.8%—230.9%
IPSCCentury Therapeutics, Inc.LTM Mar 2026-$116.94M -258.1%——
Peer median (excluding LCTX) -$61.31M-59.8%—136.9%

Competitors are the stored peer set for LCTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue3.9M14.7M8.95M9.5M14.56M
Cost of Revenue1.43M728K671K334K845K
Gross Profit2.47M13.98M8.27M9.17M13.71M
Gross Margin63.4%95.0%92.5%96.5%94.2%
Research & Development33.91M13.99M15.71M12.47M17.73M
Selling, General & Admin18.21M22.51M17.3M18.17M18.46M
Operating Expenses51.68M36.5M33.01M30.64M35.49M
Depreciation & Amortization873K727K692K609K699K
EBITDA(42.4M)(25.09M)(22.59M)(17.97M)(67.95M)
EBITDA Margin-1088.2%-170.6%-252.5%-189.2%-466.8%
Operating Income(49.21M)(22.52M)(24.73M)(21.48M)(21.78M)
Operating Margin-1263.1%-153.2%-276.5%-226.1%-149.6%
Interest Income2K829K1.63M1.72M1.69M
Interest Expense00000
Other Income / Expenses5.94M(3.29M)1.45M2.9M(46.87M)
Income Before Tax(43.27M)(25.81M)(23.28M)(18.58M)(68.65M)
Pre-Tax Margin-1110.6%-175.6%-260.3%-195.6%-471.6%
Income Tax Expense0541K(1.8M)0(5.11M)
Net Income(43.02M)(26.27M)(21.49M)(18.61M)(63.53M)
Net Margin-1104.2%-178.7%-240.2%-195.9%-436.5%
EPS (Basic)(0.26)(0.15)(0.12)(0.09)(0.28)
EPS (Diluted)(0.26)(0.15)(0.12)(0.09)(0.28)
Weighted Avg Shares164.5M169.79M172.66M200.19M230.12M
Weighted Avg Shares (Diluted)164.5M169.79M172.66M200.19M230.12M

Lineage Cell Therapeutics, Inc.

AMEX:LCTX

Intrinsic Alpha fair value

Locked

Current Price

$0.84

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.